Acurx Pharmaceuticals, Inc.

Acurx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing a new class of small-molecule antibiotics for difficult-to-treat Gram-positive bacterial infections. The company’s lead program, ibezapolstat, is designed to inhibit DNA polymerase IIIC, a target intended to selectively block Gram-positive bacteria and address antimicrobial resistance. Its pipeline is aimed at priority pathogens such as C. difficile, MRSA, VRE, drug-resistant Streptococcus pneumoniae, and anthrax-related threats. Acurx was founded in 2017, began operations in 2018, and remains in the development and regulatory stage with no commercial product revenue to date.

2.54

2.54

— Acurx Pharmaceuticals, Inc.
%
Lead clinical antibiotic candidate70% Development of ibezapolstat for difficult-to-treat C. difficile infection.
Antibiotic discovery platform20% GPSS® chemistry and target-based discovery work for Gram-positive pathogens.
Preclinical pipeline10% Earlier-stage programs aimed at MRSA, VRE, DRSP and anthrax threats.

Acurx does not currently sell approved products, so its near-term 'customers' are primarily regulators, clinical...

  • Regulatory and clinical development ecosystemprimary

    FDA, EMA, CROs, investigators and trial sites that support advancement of ibezapolstat through clinical and CMC milestones.

  • Hospital and acute-care providersprimary

    Potential future buyers of an approved C. difficile therapy for hospitalized patients with difficult-to-treat infections.

  • Third-party payorssecondary

    Government and private insurers that would influence reimbursement, formulary access and net pricing after approval.

  • Infectious disease specialistssecondary

    Physicians who would prescribe the product based on efficacy, safety and resistance profile.

Acurx is headquartered in Staten Island, New York, and operates as a U.S.-based development company...

  • •Headquartered in Staten Island, New York, United States
  • •Primary regulatory interface is the U.S. FDA
  • •EMA scientific advice supports a potential EU development path
  • •Development activity is concentrated in the U.S. clinical ecosystem
  • •No disclosed commercial revenue geography because the company has no sales

Acurx’s strategy is centered on advancing ibezapolstat through late-stage clinical development and regulatory...

01
Complete late-stage development of ibezapolstatshort-term

The lead asset is the main source of future value and the clearest path to commercialization.

02
Maintain financing capacityshort-term

The company has no product revenue and depends on external capital to fund clinical and regulatory work.

03
Broaden the antibiotic pipelinemedium-term

A broader portfolio can reduce single-asset risk and increase long-term partnering or commercialization options.

Acurx faces the core risks typical of a clinical-stage biotech company: no approved products, no revenue, and heavy...

critical

Clinical-stage execution risk

The company has limited operating history and must successfully complete development before any commercial revenue can be generated.

Scope
Lead program ibezapolstat and broader pipeline
Materiality
high
critical

Regulatory approval risk

FDA and EMA decisions determine whether the company can advance to commercialization and access markets.

Scope
Phase 3 readiness, CMC, marketing authorization
Materiality
high
high

Financing and dilution risk

Operations are funded primarily through equity financings, warrant exercises and other capital raises rather than operating cash flow.

Scope
Ongoing corporate funding
Materiality
high
high

Reimbursement and pricing pressure

Even approved antibiotics may face payer scrutiny, managed-care restrictions and pricing challenges.

Scope
Future hospital and insurer adoption
Materiality
medium
medium

Competition from larger pharmaceutical companies

Competitors may have greater R&D, manufacturing, regulatory and commercialization resources.

Scope
Anti-infective market
Materiality
medium
Research and development expense recognition
Affects operating loss and quarterly comparability
Accrued expenses
Can materially change reported liabilities and expenses
Share-based compensation
Affects net loss and operating expense presentation
Deferred R&D prepayments
Shifts expense timing between periods

Vincerx Pharma, Inc.

Pharmaceutical Preparations

Cocrystal Pharma, Inc.

COCP · Pharmaceutical Preparations

CalciMedica, Inc.

CALC · Pharmaceutical Preparations

Aardvark Therapeutics, Inc.

AARD · Pharmaceutical Preparations

BIOCRYST PHARMACEUTICALS INC

BCRX · Biological Products, (No Diagnostic Substances)

LadRx Corp

Biological Products, (No Diagnostic Substances)

: 11/08/2026